A Phase 3 interventional study of Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine and Meningococcal Group B vaccine (Trumenba®) in Meningococcal Immunisation (Healthy Volunteers), sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 30 sites in 2 countries. Open to participants aged 13 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objective:
To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine:
Secondary Objective:
To describe:
Study duration per participant was approximately 6 months including: 1 day of screening and vaccination, 1 or 2 additional visits at Day 6 and Day 30, 2 phone calls and a safety follow-up/end of study visit, at Day 8 and Day 180 after vaccine administration, respectively.
Safety assessment included solicited reactions within 7 days after vaccination, unsolicited adverse events (AEs) up to 30 days after vaccination, serious adverse events (SAEs) throughout the study.
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).
Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine · Biological: Meningococcal Group B vaccine (Trumenba®)
Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).
Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine · Biological: Meningococcal group B vaccine (Bexsero®)
Pharmaceutical form: Solution for injection Route of administration: IM
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Also known as: Trumenba®
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Also known as: Bexsero®
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by Serum Bactericidal Assay Using Human Complement (hSBA). The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer greater than or equal to (\>=) 1:16 for participants with pre-vaccination hSBA titer less than (\<) 1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>= 1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.
Time frame: Day 30 (post-vaccination) in study MET59
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 2
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.
Time frame: Day 30 (post-vaccination) in study MET59
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.
Time frame: Day 6 (post-vaccination) in study MET59
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
Time frame: Day 6 (post-vaccination) in study MET59
Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Time frame: Day 6 (post-vaccination) in study MET59
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.
Time frame: Day 30 (post-vaccination) in study MET59
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
Antibody titers against meningococcal serogroups A, C, W, and Y were measured by hSBA. Seroprotection were defined as hSBA titer \>=1:8.
Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
Time frame: Day 0 (pre-vaccination) in study MET59
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Time frame: Day 0 (pre-vaccination) in study MET59
Percentage of Participants Achieving Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post-Vaccination in Study MET50 or MET43
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
Time frame: Day 0 (pre-vaccination), Day 30 (post-vaccination) in study MET50 or MET43
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post Vaccination in Either Study MET50 or MET43 and Pre Vaccination in Study MET59
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET50 or MET43; Day 0 (pre-vaccination) in study MET59
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.
Time frame: Day 30 (post-vaccination) in study MET59
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
Study participants were enrolled from 03-September-2019 to 07-March-2020 at 30 active sites in the United States and Puerto Rico.
| Milestone | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine |
|---|---|---|---|---|
| Started | 191 | 190 | 95 | 94 |
| Safety analysis set (safas) | 186 | 184 | 93 | 92 |
| Full analysis set | 191 | 190 | 95 | 94 |
| Per-protocol analysis set 1 (ppas1) | 46 | 45 | 0 | 0 |
| Per-protocol analysis set 2 (ppas2) | 174 | 176 | 90 | 89 |
| Completed | 187 | 186 | 95 | 92 |
| Not completed | 4 | 4 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 3 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by Serum Bactericidal Assay Using Human Complement (hSBA). The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer greater than or equal to (\>=) 1:16 for participants with pre-vaccination hSBA titer less than (\<) 1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>= 1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine |
|---|---|
| Serogroup A | 94.8 (90.4 to 97.6) |
| Serogroup C | 97.1 (93.4 to 99.1) |
| Serogroup Y | 98.9 (95.9 to 99.9) |
| Serogroup W | 97.7 (94.2 to 99.4) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.
| percentage of participants | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|
| Serogroup A | 93.2 (88.4 to 96.4) |
| Serogroup C | 98.9 (96.0 to 99.9) |
| Serogroup Y | 100 (97.9 to 100) |
| Serogroup W | 98.9 (96.0 to 99.9) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A | 82.6 (68.6 to 92.2) | 77.8 (62.9 to 88.8) |
| Serogroup C | 89.1 (76.4 to 96.4) | 93.3 (81.7 to 98.6) |
| Serogroup Y | 95.7 (85.2 to 99.5) | 91.1 (78.8 to 97.5) |
| Serogroup W | 97.8 (88.5 to 99.9) | 88.9 (75.9 to 96.3) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A | 91.3 (79.2 to 97.6) | 95.6 (84.9 to 99.5) |
| Serogroup C | 100 (92.3 to 100) | 97.8 (88.2 to 99.9) |
| Serogroup Y | 97.8 (88.5 to 99.9) | 100 (92.1 to 100) |
| Serogroup W | 100 (92.3 to 100) | 100 (92.1 to 100) |
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
| titers | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A | 289 (133 to 625) | 161 (93.0 to 280) |
| Serogroup C | 3799 (2504 to 5763) | 919 (500 to 1690) |
| Serogroup Y | 1658 (973 to 2826) | 800 (467 to 1371) |
| Serogroup W | 1928 (1187 to 3131) | 708 (463 to 1082) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A | 94.8 (90.4 to 97.6) | 93.2 (88.4 to 96.4) |
| Serogroup C | 97.1 (93.4 to 99.1) | 98.9 (96.0 to 99.9) |
| Serogroup Y | 98.9 (95.9 to 99.9) | 100 (97.9 to 100) |
| Serogroup W | 97.7 (94.2 to 99.4) | 98.9 (96.0 to 99.9) |
Antibody titers against meningococcal serogroups A, C, W, and Y were measured by hSBA. Seroprotection were defined as hSBA titer \>=1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A: Day 0 | 71.3 (63.9 to 77.9) | 71.0 (63.7 to 77.6) |
| Serogroup A: Day 30 | 99.4 (96.8 to 100) | 99.4 (96.9 to 100) |
| Serogroup C: Day 0 | 87.9 (82.1 to 92.4) | 50.6 (42.9 to 58.2) |
| Serogroup C: Day 30 | 100 (97.9 to 100) | 100 (97.9 to 100) |
| Serogroup Y: Day 0 | 79.9 (73.2 to 85.6) | 52.8 (45.2 to 60.4) |
| Serogroup Y: Day 30 | 100 (97.9 to 100) | 100 (97.9 to 100) |
| Serogroup W: Day 0 | 86.2 (80.2 to 91.0) | 77.8 (71.0 to 83.7) |
| Serogroup W: Day 30 | 100 (97.9 to 100) | 100 (97.9 to 100) |
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
| titers | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A: Day 0 | 11.7 (9.89 to 13.8) | 11.5 (9.72 to 13.7) |
| Serogroup A: Day 30 | 502 (388 to 649) | 399 (318 to 502) |
| Serogroup C: Day 0 | 36.6 (28.8 to 46.7) | 10.2 (8.03 to 13.0) |
| Serogroup C: Day 30 | 3708 (3146 to 4369) | 2533 (2076 to 3091) |
| Serogroup Y: Day 0 | 20.5 (16.6 to 25.2) | 8.35 (6.70 to 10.4) |
| Serogroup Y: Day 30 | 2308 (1925 to 2767) | 3036 (2547 to 3620) |
| Serogroup W: Day 0 | 27.0 (22.0 to 33.1) | 14.8 (12.2 to 18.1) |
| Serogroup W: Day 30 | 2290 (1934 to 2711) | 2574 (2178 to 3041) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine |
|---|---|---|---|---|
| Serogroup A | 72.3 (65.3 to 78.5) | 71.1 (64.0 to 77.4) | 73.7 (63.6 to 82.2) | 73.1 (62.9 to 81.8) |
| Serogroup C | 86.9 (81.3 to 91.3) | 52.6 (45.3 to 59.9) | 86.3 (77.7 to 92.5) | 85.1 (76.3 to 91.6) |
| Serogroup Y | 79.1 (72.6 to 84.6) | 55.3 (47.9 to 62.5) | 88.3 (80.0 to 94.0) | 80.9 (71.4 to 88.2) |
| Serogroup W | 86.9 (81.3 to 91.3) | 77.9 (71.3 to 83.6) | 90.5 (82.8 to 95.6) | 91.4 (83.8 to 96.2) |
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
| titers | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine |
|---|---|---|---|---|
| Serogroup A | 12.3 (10.5 to 14.5) | 12.2 (10.2 to 14.6) | 12.8 (10.0 to 16.3) | 12.7 (9.70 to 16.6) |
| Serogroup C | 34.5 (27.4 to 43.6) | 11.9 (9.17 to 15.3) | 38.4 (27.3 to 54.0) | 43.3 (29.8 to 63.0) |
| Serogroup Y | 19.8 (16.2 to 24.2) | 9.19 (7.39 to 11.4) | 26.0 (19.6 to 34.5) | 22.0 (16.1 to 30.0) |
| Serogroup W | 27.4 (22.4 to 33.4) | 15.1 (12.5 to 18.3) | 28.1 (21.8 to 36.2) | 32.7 (24.5 to 43.7) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
| percentage of participants | Pooled Groups 1, 3 and 4: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A: Day 0 of MET50 or MET43 | 54.5 (49.3 to 59.6) | 35.8 (27.7 to 44.6) |
| Serogroup A: Day 30 of MET50 or MET43 | 94.7 (91.9 to 96.7) | 81.2 (73.5 to 87.5) |
| Serogroup C: Day 0 of MET50 or MET43 | 18.6 (14.8 to 22.9) | 12.7 (7.6 to 19.5) |
| Serogroup C: Day 30 of MET50 or MET43 | 98.1 (96.2 to 99.2) | 74.2 (65.9 to 81.5) |
| Serogroup Y: Day 0 of MET50 or MET43 | 4.5 (2.7 to 7.1) | 3.7 (1.2 to 8.5) |
| Serogroup Y: Day 30 of MET50 or MET43 | 97.9 (95.9 to 99.1) | 88.7 (82.1 to 93.5) |
| Serogroup W: Day 0 of MET50 or MET43 | 39.9 (34.9 to 45.0) | 40.3 (31.9 to 49.1) |
| Serogroup W: Day 30 of MET50 or MET43 | 100 (99.0 to 100) | 93.2 (87.5 to 96.9) |
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
| titers | Pooled Groups 1, 3 and 4: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) |
|---|---|---|
| Serogroup A: Day 0 of MET50 or MET43 | 7.28 (6.53 to 8.11) | 5.72 (4.75 to 6.87) |
| Serogroup A: Day 30 of MET50 or MET43 | 45.2 (39.9 to 51.1) | 32.8 (25.0 to 43.1) |
| Serogroup A: Day 0 of MET59 | 12.5 (11.1 to 14.1) | 11.6 (9.41 to 14.3) |
| Serogroup C: Day 0 of MET50 or MET43 | 3.48 (3.22 to 3.76) | 2.98 (2.69 to 3.30) |
| Serogroup C: Day 30 of MET50 or MET43 | 417 (348 to 500) | 49.7 (32.4 to 76.4) |
| Serogroup C: Day 0 of MET59 | 37.5 (31.6 to 44.5) | 11.0 (8.09 to 14.9) |
| Serogroup Y: Day 0 of MET50 or MET43 | 2.36 (2.22 to 2.50) | 2.30 (2.13 to 2.48) |
| Serogroup Y: Day 30 of MET50 or MET43 | 91.0 (78.6 to 105) | 36.1 (27.2 to 47.8) |
| Serogroup Y: Day 0 of MET59 | 21.8 (18.8 to 25.1) | 8.49 (6.50 to 11.1) |
| Serogroup W: Day 0 of MET50 or MET43 | 5.34 (4.76 to 6.00) | 5.54 (4.57 to 6.72) |
| Serogroup W: Day 30 of MET50 or MET43 | 82.7 (73.6 to 92.9) | 45.1 (34.3 to 59.4) |
| Serogroup W: Day 0 of MET59 | 28.8 (25.1 to 33.0) | 14.9 (11.9 to 18.6) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine | Pooled Groups 3 and 4: MenACYW Conjugate Vaccine |
|---|---|---|---|---|
| Serogroup A | 94.8 (90.4 to 97.6) | 93.3 (86.1 to 97.5) | 95.5 (88.8 to 98.7) | 94.4 (89.9 to 97.3) |
| Serogroup C | 97.1 (93.4 to 99.1) | 97.8 (92.2 to 99.7) | 96.6 (90.4 to 99.3) | 97.2 (93.6 to 99.1) |
| Serogroup Y | 98.9 (95.9 to 99.9) | 98.9 (93.9 to 100) | 97.8 (92.1 to 99.7) | 98.3 (95.2 to 99.7) |
| Serogroup W | 97.7 (94.2 to 99.4) | 98.9 (94.0 to 100) | 96.6 (90.4 to 99.3) | 97.8 (94.3 to 99.4) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine | Pooled Groups 3 and 4: MenACYW Conjugate Vaccine |
|---|---|---|---|---|
| Serogroup A: Day 0 | 71.3 (63.9 to 77.9) | 73.3 (63.0 to 82.1) | 71.6 (61.0 to 80.7) | 72.5 (65.3 to 78.9) |
| Serogroup A: Day 30 | 99.4 (96.8 to 100) | 98.9 (94.0 to 100) | 100 (95.9 to 100) | 99.4 (96.9 to 100) |
| Serogroup C: Day 0 | 87.9 (82.1 to 92.4) | 86.7 (77.9 to 92.9) | 86.5 (77.6 to 92.8) | 86.6 (80.7 to 91.2) |
| Serogroup C: Day 30 | 100 (97.9 to 100) | 100 (96.0 to 100) | 100 (95.9 to 100) | 100 (97.9 to 100) |
| Serogroup Y: Day 0 | 79.9 (73.2 to 85.6) | 89.9 (81.7 to 95.3) | 80.9 (71.2 to 88.5) | 85.4 (79.3 to 90.2) |
| Serogroup Y: Day 30 | 100 (97.9 to 100) | 100 (96.0 to 100) | 100 (95.9 to 100) | 100 (98.0 to 100) |
| Serogroup W: Day 0 | 86.2 (80.2 to 91.0) | 91.1 (83.2 to 96.1) | 90.9 (82.9 to 96.0) | 91.0 (85.8 to 94.8) |
| Serogroup W: Day 30 | 100 (97.9 to 100) | 100 (96.0 to 100) | 100 (95.9 to 100) | 100 (98.0 to 100) |
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
| titers | Group 1: MenACYW Conjugate Vaccine | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine | Pooled Groups 3 and 4: MenACYW Conjugate Vaccine |
|---|---|---|---|---|
| Serogroup A: Day 0 | 11.7 (9.89 to 13.8) | 12.5 (9.78 to 16.0) | 12.3 (9.37 to 16.2) | 12.4 (10.4 to 14.9) |
| Serogroup A: Day 30 | 502 (388 to 649) | 593 (426 to 825) | 667 (477 to 933) | 629 (498 to 794) |
| Serogroup C: Day 0 | 36.6 (28.8 to 46.7) | 37.6 (26.6 to 53.3) | 42.4 (29.4 to 61.0) | 39.9 (31.1 to 51.2) |
| Serogroup C: Day 30 | 3708 (3146 to 4369) | 4741 (3882 to 5791) | 3472 (2667 to 4518) | 4064 (3446 to 4793) |
| Serogroup Y: Day 0 | 20.5 (16.6 to 25.2) | 25.5 (19.4 to 33.6) | 21.0 (15.4 to 28.7) | 23.2 (18.9 to 28.5) |
| Serogroup Y: Day 30 | 2308 (1925 to 2767) | 2600 (2042 to 3311) | 2469 (1881 to 3241) | 2534 (2117 to 3034) |
| Serogroup W: Day 0 | 27.0 (22.0 to 33.1) | 28.3 (22.0 to 36.4) | 30.0 (22.5 to 40.1) | 29.1 (24.1 to 35.2) |
| Serogroup W: Day 30 | 2290 (1934 to 2711) | 2702 (2134 to 3422) | 2064 (1601 to 2662) | 2363 (1988 to 2810) |
Collected over Unsolicited adverse event (AE) data were collected from Day 0 (pre-vaccination) up to Day 30 (post-vaccination) in MET59. The solicited reactions (SR) were collected within 7 days post-vaccination in MET59. Serious AEs data were collected up to 30 days post-vaccination in MET59.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | 0/186 (0%) | 2/186 (1.1%) | 129/186 (69.4%) |
| Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | 0/184 (0%) | 2/184 (1.1%) | 116/184 (63%) |
| Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | 0/93 (0%) | 2/93 (2.2%) | 83/93 (89.2%) |
| Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine | 0/92 (0%) | 0/92 (0%) | 88/92 (95.7%) |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine |
|---|---|---|---|---|
| Accidental OverdoseInjury, poisoning and procedural complications | 0/186 | 0/184 | 1/93 | 0/92 |
| Major DepressionPsychiatric disorders | 0/186 | 0/184 | 1/93 | 0/92 |
| Suicidal IdeationPsychiatric disorders | 1/186 | 1/184 | 1/93 | 0/92 |
| AppendicitisInfections and infestations | 1/186 | 1/184 | 0/93 | 0/92 |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine |
|---|---|---|---|---|
| Injection Site PainGeneral disorders | 71/186 | 63/184 | 77/93 | 85/92 |
| MyalgiaMusculoskeletal and connective tissue disorders | 61/186 | 64/184 | 60/93 | 58/92 |
| HeadacheNervous system disorders | 68/186 | 67/184 | 41/93 | 36/92 |
| MalaiseGeneral disorders | 50/186 | 47/184 | 36/93 | 37/92 |
| Injection Site SwellingGeneral disorders | 10/186 | 3/184 | 12/93 | 15/92 |
| Injection Site ErythemaGeneral disorders | 12/186 | 10/184 | 15/93 | 14/92 |
| NasopharyngitisInfections and infestations | 9/186 | 6/184 | 5/93 | 2/92 |
| Upper Respiratory Tract InfectionInfections and infestations | 10/186 | 8/184 | 1/93 | 1/92 |
Analysis was performed on all enrolled participants.
| Age, Continuous(years) | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine | Total |
|---|---|---|---|---|---|
| Mean | 15.4 ± 1.59 | 15.8 ± 1.37 | 15.1 ± 1.12 | 15.3 ± 1.34 | 15.4 ± 1.43 |
| Sex: Female, Male(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine | Total |
|---|---|---|---|---|---|
| Female | 99 | 85 | 41 | 45 | 270 |
| Male | 92 | 105 | 54 | 49 | 300 |
| Race (NIH/OMB)(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) | Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine | Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 | 2 |
| Black or African American | 19 | 16 | 7 | 7 | 49 |
| White | 163 | 165 | 83 | 86 | 497 |
| More than one race | 8 | 6 | 5 | 0 | 19 |
| Unknown or Not Reported | 0 | 3 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2019 to primary completion in Sep 2020, 12 months.
Results were first posted in Aug 2021, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine
Sanofi Pasteur, a Sanofi Company →